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ABSTRACT
Circulating Tumour Cells (CTCs) are promising cancer biomarkers. Several 
methods have been developed to isolate CTCs from blood samples. However, the 
isolation of melanoma CTCs is very challenging as a result of their extraordinary 
heterogeneity, which has hindered their biological and clinical study. Thus, methods 
that isolate CTCs based on their physical properties, rather than surface marker 
expression, such as microfluidic devices, are greatly needed in melanoma. Here, we 
assessed the ability of the slanted spiral microfluidic device to isolate melanoma CTCs 
via label-free enrichment. We demonstrated that this device yields recovery rates of 
spiked melanoma cells of over 80% and 55%, after one or two rounds of enrichment, 
respectively. Concurrently, a two to three log reduction of white blood cells was 
achieved with one or two rounds of enrichment, respectively. We characterised the 
isolated CTCs using multimarker flow cytometry, immunocytochemistry and gene 
expression. The results demonstrated that CTCs from metastatic melanoma patients 
were highly heterogeneous and commonly expressed stem-like markers such as PAX3 
and ABCB5. The implementation of the slanted microfluidic device for melanoma CTC 
isolation enables further understanding of the biology of melanoma metastasis for 
biomarker development and to inform future treatment approaches.
INTRODUCTION
Metastatic disease occurs in approximately 10% of 
melanoma patients at diagnosis and drastically reduces 
survival in the first year after diagnosis [1, 2]. Despite 
remarkable advances in the treatment of melanoma, only 
20% of patients with metastatic spread show long lasting 
responses (>2 years) to current treatments [3–6]. Thus, 
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a better understanding of the pathogenic mechanisms 
underlying metastatic spread will ultimately lead to the 
discovery of biomarkers that predict, with high reliability, 
clinical outcome and treatment response, a critical unmet 
need for melanoma.
Circulating tumour cells (CTCs), are the tumour 
seeds responsible for metastatic haematogenous 
dissemination of solid tumours and arise from both 
primary and secondary tumours. Since CTCs can be 
detected and isolated from blood, phenotypic and 
genetic characterisation of these cells provides insightful 
information about the biology of melanoma metastasis, 
as well as the evolving phenotype and genotype of all 
concurrent tumours within a patient [7]. The ease of access 
of CTCs from blood for repeated sampling, exemplifies 
CTCs as invaluable biomarkers for real-time monitoring 
of clinical status and treatment response [8, 9]. In 
melanoma, cumulative evidence supports a role for CTCs 
in the prediction of clinical outcome and monitoring of 
therapeutic response [10–14].
Despite the potential biomarker utility of CTCs, 
the isolation and detection of these cells is a significant 
technical challenge that must be overcome to achieve 
a better understanding of their biology and role in 
metastasis, as well as for their implementation in the 
clinic. Firstly, CTCs are extremely rare in the blood of 
melanoma patients (i.e. 1-10 cells per 8 mL of blood) 
[10–12, 15–17], demanding methods that isolate CTCs 
at a high recovery rate and with a low background of 
white blood cells (WBCs). Secondly, the high phenotypic 
heterogeneity observed in melanoma CTCs adds 
significant complexity, with no single marker detecting the 
majority of melanoma CTCs [10, 13, 15, 16, 18]. This is in 
contrast with the use of the cell surface marker, EpCAM 
(epithelial cell adhesion molecule) [19] and the internal 
marker, cytokeratin, standard CTC markers for epithelial 
cancer cells [20–23]. Thus, conventional isolation methods 
that depend on the expression of cell surface markers (i.e. 
label-dependent methods) are not optimal in melanoma 
and provide a biased isolation outcome [7]. Instead, label-
independent isolation methods (i.e. microfluidic devices) 
may provide a solution, as they utilise differential cell 
size, density and rigidity to enrich CTCs from blood [18, 
24–27]. Various microfluidic devices have been developed 
and validated for isolation of CTCs from patients with 
different types of cancer, mainly of epithelial origin, 
such as micro-fabricated filters [28, 29], electric-based 
approaches [30], the herringbone CTC-Chip [31], CTC-
iChip [32], Cluster-Chip [18], Parsortix [26, 33] and 
spiral-based chips [24, 34].
In melanoma, microfluidic devices (i.e. herringbone 
CTC-Chip, CTC-iChip or Cluster-Chip) have been used 
to isolate single or cluster CTCs from metastatic patients 
before [13, 18, 32] and during treatment with MAPK 
inhibitors [13]. However, additional isolation methods 
that yield a viable, label-free and more diverse fraction of 
CTCs are urgently required for the isolation of melanoma 
CTCs. The implementation of such methods in melanoma 
is also critical for downstream applications, such as 
genetic and phenotypic characterisation of CTCs, cell 
culture and CTC-derived xenotransplantion, which will 
provide an insight into the biology of CTCs and melanoma 
metastasis [18, 35–38].
Spiral microfluidic devices, which rely on “Dean 
drag” forces, have been recently developed to isolate 
CTCs based on cell size, deformability and density 
with high purity, viability and recovery efficiency [24, 
34, 39]. These spiral devices have demonstrated their 
superiority over the only FDA-approved platform for CTC 
enumeration, CellSearch® (Janssen Diagnostics LLC), in 
the recovery of CTCs in breast and lung cancer patients 
[34]. Particularly, the slanted spiral device has been shown 
to yield recovery rates of over 80% with spiked breast and 
bladder cancer cells, and to isolate and detect CTCs in 
almost all the analysed blood samples from patients with 
metastatic breast and lung cancer [24]. But no report has 
been shown its utility for the isolation of melanoma CTCs. 
This device has the advantageous capability of being able 
to process 8 mL of blood sample in less than 10 minutes to 
yield CTCs at relatively high purity (500 WBCs per mL of 
processed blood) [24], compared to over an hour by other 
microfluidic devices [18, 25, 31–33, 39]. In addition, short 
term cell cultures of CTCs from breast cancer patients 
have been established after isolation of CTCs through this 
slanted device, demonstrating the high viability of CTCs 
isolated through this device, as a result of the low shear 
stress caused to the cells [38].
Here, we validate the ability of the slanted spiral 
microfluidic device to isolate a viable, label-free and 
heterogeneous population of CTCs from the blood of 
melanoma patients with metastatic disease. Furthermore, 
this enrichment allowed us to interrogate the phenotype 
and gene expression profile of CTCs isolated from 
metastatic melanoma patients prior to treatment, using 
multimarker flow cytometry, gene expression analysis and 
immunofluorescence staining.
RESULTS
Recovery and purity of melanoma cells with 
different cell size
To determine the efficiency of the slanted spiral 
microfluidic device to isolate circulating melanoma cells 
of different cell sizes, we firstly classified the melanoma 
cell lines 1205Lu, A2058, SKMEL5, UACC62, WM164 
and WM793, based on their cell size, inferred by forward 
scatter values in a flow cytometer platform (Supplementary 
Figure 2). A2058 and SKMEL5 were respectively 
identified as the cell lines with the smallest (mean cell 
diameter: 14 μm) and largest cell size (mean cell diameter: 
18 μm), and the mean cell diameters significantly differed 
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between these two melanoma cell lines (P=0.0002) (Figure 
1A). We spiked blood from healthy individuals with 
increasing amounts of these cell lines and processed them 
through the slanted spiral microfluidic device. An overall 
average recovery rate of 83% was observed across all 
the spiked blood samples with either A2058 or SKMEL5 
cells, and no significant differences were observed in the 
recovery rates for each melanoma cell line, regardless 
of the number of cells spiked (Figure 1B). To assess the 
purity of the enriched fraction, we quantified WBCs in the 
sample before and after processing through the slanted 
device. We achieved a 2 log reduction in the number of 
WBCs after processing the sample once (1X slanted) 
through this device (mean: 2.0 x 105; range: 0.7 - 4.2 x 
105) compared to the initial WBC count (mean: 1.5 x 107, 
range: 1.2 - 1.7 x 107) (Figure 1C).
A second slanted enrichment was performed (2X 
slanted) with the purpose of further reducing the WBC 
background for future genetic interrogation of the CTC 
fraction. This resulted in a total 3 log WBC reduction 
(mean: 1 x 104; range: 0.7-4 x 104) after 2X slanted 
enrichment (Figure 1C). We measured the recovery rates 
of the 2X slanted enrichment by spiking 50 A2058 or 
SKMEL5 cells into healthy donor blood to determine 
whether a second slanted enrichment could yield an 
enriched sample with a higher purity without loss in 
recovery of melanoma cells. We obtained an average 
recovery rate of 74% for A2058 and 55% for SKMEL5 
cells (Figure 1D).
Next we proceeded to analyse CTCs in melanoma 
patient blood samples, firstly assessing the purity and 
secondly identifying CTCs in the CTC-enriched samples 
after slanted enrichment. To determine the level of purity 
of CTC fractions from patients after enrichment with the 
slanted spiral device, we counted WBCs before and after 
processing 8 mL of blood from 5 metastatic melanoma 
patients once and twice through the slanted spiral device. 
On average, we again found a 2-3 log reduction in WBCs 
relative to the initial WBC count (mean: 3.5 x 107 WBCs 
(range: 2.4 x 107 - 4.9 x 107), after 1X slanted, 7.7 x 105 
WBCs (range: 245,000 – 465,500) and after 2X slanted, 
8.6 x 104 WBCs (range: 49,105 – 123,203). Thus, a 
second round of enrichment through the slanted device 
demonstrated its ability to significantly deplete WBCs 
with high significance in both control and patient samples 
(P<0.0001), even though WBC levels were higher in 
patients than in healthy controls (Figure 1C). Samples 
from these 5 patients were included in the CTC detection 
experiments detailed below.
Detection of CTCs by flow cytometry before and 
after slanted enrichment
In order to demonstrate the presence of melanoma 
cells in the ‘CTC fraction’ after enrichment through the 
slanted spiral device, we processed blood samples from 10 
metastatic melanoma patients, prior to treatment (baseline) 
(Table 1). The ‘CTC fraction’ was stained with multiple 
markers and analysed by flow cytometry, as previously 
described by Gray et al. [10]. Results were compared to 
the number of CTCs observed in a separate sample from 
each patient without slanted enrichment but analysed 
by flow cytometry. This flow cytometry assay identifies 
subpopulations of CTCs based on their positivity for 
melanoma-associated markers, MCAM (melanoma cell 
adhesion molecule) and MCSP (melanoma-associated 
chondroitin sulphate proteoglycan), and/or their positivity 
for melanoma-initiating cell markers, ABCB5 (ATP-
binding cassette subfamily B member 5), CD271 and 
RANK (Receptor Activator of NFkβ pathway) [10].
Using this approach, we detected CTCs in 7 out of 
10 patients, with a median of 5 CTCs (range: 1 - 565) 
in 8 mL of blood, before any slanted enrichment. As 
previously described [10], we observed high diversity in 
the phenotype of CTCs detected in these patients before 
slanted enrichment. ABCB5 was the most common marker 
of CTCs, and RANK was the second most common 
marker, expressed either alone or in combination with 
ABCB5. Melanoma-associated markers MCSP and 
MCAM were not detected on any CTCs isolated from 
the 10 metastatic melanoma patients (Figure 2). We also 
detected CTCs post slanted enrichment in 4 out the 7 
CTC positive patients, though at lower numbers (1-62 
CTCs) (Figure 2). The 6 cases with no CTCs detected 
after processing through the microfluidic device had low 
or no CTC counts (0-6 CTCs) prior to any enrichment. In 
contrast, cases with detected CTCs after slanted processing 
had much higher initial CTC counts (24-565 CTCs in 
8 mL of blood). The phenotype of the cells isolated by 
the slanted device were present prior to enrichment, 
albeit at different frequencies. The melanoma-initiating 
marker ABCB5 remained the most common marker after 
slanted enrichment and was observed to be more highly 
represented after enrichment than the other CTC markers.
Molecular detection of melanoma-specific 
transcript levels in enriched fractions
We also characterised the melanoma cells in the 
‘CTC fraction’ after slanted enrichment by assessing the 
gene expression of 5 melanoma-associated genes [40]. 
The genes included: MLANA/MART1 (melanoma antigen 
recognized by T cells), TYR (tyrosinase), MAGEA3 
(melanoma antigen family A3), PAX3 (paired box 
protein Pax-3 isoform 3) and ABCB5. These genes were 
selected based on their known exclusive expression in 
melanoma cells and their undetected expression by this 
RT-PCR assay in WBC samples from healthy individuals 
(n=5). Moreover, these genes are either known markers 
of melanoma pathology, due to their high expression 
in melanoma tumours, and/or involved in melanoma 
pathogenesis [41–44].
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First we assessed whether we can detect these 5 
genes in RNA extracted from samples containing 1, 5, 
10 and 20 melanoma cells spiked into 100,000 WBCs, 
the level of WBC background observed after 2X slanted 
enrichment (Figure 1C). Transcripts of MLANA, TYR, 
MAGEA3, PAX3, and ABCB5 were successfully identified 
from a single melanoma cell, as reflected by the increase 
in reciprocal Ct values (1/Ct) (Figure 3).
In patient samples, we detected melanoma specific 
transcripts in 7 out of 13 (54%) CTC enriched fractions 
from metastatic melanoma patients. In particular, the PAX3 
transcripts were detected exclusively in 3 out of the 7 
positive CTC-enriched samples, while also detected along 
with ABCB5 in another 2 cases (thus 5/7 cases). ABCB5 
and MLANA transcripts were detected alone in one patient 
each (Figure 3). Differences in 18S rRNA Ct values 
across all analysed samples were a result of differential 
WBC counts in the CTC fractions across all patients. 
Interestingly, all the 7 patients with detected PAX3, 
ABCB5 or MLANA transcripts by RT-PCR had metastatic 
disease in distant organs (stage M1c) and two of three 
cases with brain metastases had CTC fractions positive 
by RT-PCR, for MLANA and PAX3. Furthermore, four of 
the patients with detected melanoma-specific transcripts 
had CTC counts higher than 155 CTCs per 8 mL of blood; 
whilst the remaining three had from 1 to 11 CTCs per 8 
mL of blood, detected by flow cytometry before slanted 
enrichment. In contrast, the patients with undetected 
transcripts had at least 1 CTC per 8 mL of blood (n= 5, 
1-81 CTCs) detected by flow cytometry before slanted 
enrichment, with only one case negative for CTCs.
Detection of melanoma CTCs using 
immunostaining
To further demonstrate the presence of CTCs 
in the enriched fractions, we developed a melanoma-
specific multimarker immunostaining protocol. Markers 
Figure 1: Recovery rates and purity of melanoma cells isolated using a slanted spiral microfluidic device. Melanoma 
cells were spiked into blood from healthy donors. (A) Comparison of the mean diameters of melanoma cell lines A2058 and SKMEL5, 
after five consecutive passages, yielded a statistically significant difference between mean diameters of both cell lines (t-test, P=0.0002). 
(B) Recovery rates of 5, 10, 50 and 100 CellTracker™ red-labelled A2058 and SKMEL5 cells spiked in blood from healthy donors after 1X 
slanted enrichment (n=3). No statistically significant differences were found in the recovery rates for A2058 (P=0.376) and SKMEL5 cell 
lines (P=0.102) between different spiked amounts. (C) WBC counts in the blood of healthy donors (controls, n=3) and metastatic melanoma 
patients (n=5) before and after the first and second round of enrichment with the slanted microfluidic device. A one-way ANOVA analysis 
determined a highly significant depletion of WBCs after the second round of enrichment with the slanted device in both controls (P<0.0001) 
and patients (P<0.0001). (D) Recovery rates of 50 A2058 and SKMEL5 cells spiked into blood after two rounds of slanted enrichment 
(controls, n=4). Error bars represent one standard deviation from the mean values across replicates.
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included MCSP, a melanoma cell surface specific marker, 
together with a mixture of internal melanocytic markers, 
gp100 (glycoprotein 100), S100, and MLANA, hereafter 
called “MEL” immunostaining. Firstly, we optimised this 
staining in A2058 cells spiked into WBCs from healthy 
volunteers (Figure 4A). Subsequently, we used this 
immunostaining protocol to detect melanoma CTCs in 
enriched fractions isolated from 7 metastatic melanoma 
patients using the slanted spiral device. Using this staining 
protocol, we observed CTCs in 3 cases (43%), with 1, 3 
and 4 CTCs in 8 mL of blood. All detected CTCs were 
positive for the combination of intracellular markers 
“MEL” but negative for MCSP staining and exhibited an 
average cell size of 16 μm (range: 13 – 21 μm) (Figure 
4B). Furthermore, two of the 3 cases with detected 
CTCs by immunostaining had melanoma metastasis in 
distant organs (stage M1c), and the remaining one had 
subcutaneous and lymph node metastases.
DISCUSSION
The isolation of CTCs is critical for the study of the 
role of these cells in the metastatic process as well as their 
utility as biomarkers in the clinical management of cancer. 
Therefore, the implementation of methods that enable the 
isolation of viable and label-free CTCs is of high biological 
and clinical significance. This is particularly important for 
isolation of CTCs from melanoma patients due to their 
diversity, since label-based capture significantly biases the 
number of CTCs that can be identified [10, 15, 16]. Here, 
we report the successful isolation of CTCs from the blood 
of metastatic melanoma patients using a slanted spiral 
Table 1: Demographic and clinical information of metastatic melanoma patients
Characteristic n % of total
Total patients enrolled 20
Age at enrolment (years)
Median 66
Range 34 - 80
Gender
Male 13 65%
Female 7 35%
Stage of disease at baseline
Stage IV
M1a 4 20%
M1b 1 5%
M1cα 15 75%
Mutational status of 
tumour
BRAF
V600E 11 55%
V600R 1 5%
V600K 1 5%
Other BRAF* 1 5%
Wildtype BRAF+ 6 30%
Prior treatment for 
(Baseline):
Pembrolizumab 10 50%
Dabrafenib + Trametinib 10 50%
* Case with BRAF N581S, NRAS G12D, MET E355K mutations. + Case with wild type status for BRAF and NRAS, but 
with KIT L576P and CTNNB1 S37F mutations. α Three cases with brain metastases.
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microfluidic device. We demonstrate, through downstream 
interrogation of the CTC phenotype by flow cytometry, 
immunostaining and gene expression analyses, that label-
free enrichment of melanoma CTCs successfully isolates 
heterogeneous subpopulations of cells.
The slanted spiral microfluidic device enabled 
us to retrieve melanoma cells with different cell sizes 
with a recovery rate similar to that observed for breast 
and bladder cancer cell lines [24]. This demonstrates 
the reliability of this device to differentially enrich for 
cancer cells regardless of cell size and cancer type; a very 
important feature in further applications of this device. 
In addition, we achieved close to a 3 log reduction of 
WBCs after a second round of slanted enrichment without 
markedly affecting enrichment efficiency. Despite a 
reduction of 2-3 log fold of WBCs in healthy donors and 
patients after one or two rounds of slanted enrichment, 
a higher leukocytic background was observed than 
that previously reported at 5 x 103 WBCs per 8 mL of 
processed sample after 1X slanted enrichment [24]. A 
higher leukocytic background in the CTC fraction in 
patient samples relative to controls is likely due to the 
observed leukocytosis exhibited by metastatic melanoma 
patients [45]. Further strategies, such as CD45 depletion 
[27] might better reduce the number of leukocytes after 
slanted enrichment for further molecular and genomic 
characterisation of melanoma CTCs. However, despite the 
need to further improve the leukocytic background yielded 
by the slanted device in controls (10,000 WBCs per 8 mL 
of blood) and patients (86,000 WBCs per 8 mL of blood), 
these values are better than those reported for CTC-iChip 
(32,000 WBCs per mL of control blood), which was 
previously used for isolation of melanoma CTCs [46]. 
More recent microfluidic platforms, such as Parsortix 
(Angle plc), have shown promising results in regards to 
WBC depletion, with approximately 2800 WBCs detected 
after processing 4 mL of blood from healthy volunteers 
[33]. Therefore, a study comparing the recovery, WBC 
depletion in patients and CTC isolation efficiencies, for 
melanoma, of the slanted spiral microfluidic relative 
to other microfluidic devices [18, 26, 32] is strongly 
encouraged. This approach will determine the best 
platform for melanoma CTC isolation to be utilised in 
further clinical studies. Nonetheless, the microfluidic 
platforms previously used for isolation of melanoma 
CTCs are not readily available [13, 18, 32].
Phenotypic analysis of CTCs before and after 
slanted enrichment, using multimarker flow cytometry 
[10], showed reduction in the number and diversity of 
CTCs being enriched by the slanted spiral microfluidic 
device. This is mainly caused by a preferential enrichment 
of CTCs expressing ABCB5 over the rest of the melanoma 
CTCs expressing other markers, particularly RANK 
expressing CTCs. Since the slanted spiral device isolates 
CTCs based on their differential cell size and density [24], 
it is possible that ABCB5+ cells vary in these physical 
Figure 2: Diversity of melanoma CTCs pre and post slanted enrichment. Comparison of phenotype and number of CTCs 
identified before and after slanted enrichment in 10 metastatic melanoma patients using multimarker flow cytometry. Bars indicate the 
number of CTCs detected by flow cytometry in each individual, with each phenotype indicated by a colour and pattern.
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Figure 3: Gene expression of 5 melanoma-specific genes in samples from healthy controls, spiked samples and CTC 
fractions from metastatic melanoma patients after slanted enrichment. Heatmap represents the expression levels of the 
melanoma-associated genes MLANA, TYR, MAGEA, ABCB5 and PAX3, which were assessed by RT-PCR. The 18S rRNA gene was used 
as an endogenous control. Cellular fractions after slanted processing of the blood from 5 healthy controls were used as negative controls. 
Spiked samples with 1, 5, 10 and 20 A2058 melanoma cells in a background of 1 x 105 WBCs were used to demonstrate the detection level 
of this assay. CTC-enriched fractions from 13 metastatic melanomas were interrogated. Spiked samples with 20 A2058 cells were used as 
positive controls in every run. Each heatmap square corresponds to the reciprocal value of the Ct values for each target gene (1/Ct) for a 
given sample.
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characteristics and might be preferentially enriched. 
Ozkumur et al. [46] have indicated a variability of 
melanoma CTCs in cell size after microfluidic isolation, 
but it is still unclear whether CTC subtypes do in fact 
vary in cell size and density. The differential recovery 
rates observed for the melanoma cell lines A2058 and 
SKMEL5 after a second round of slanted might support 
this preferential enrichment. It is possible that these cell 
lines may not only differ in size but also in other physical 
properties such as cell density or deformability, explaining 
the differential recovery observed. Nevertheless, despite 
the reduction in number and diversity of melanoma CTCs 
after slanted enrichment, we did obtain a heterogeneous 
fraction of CTCs, identified by another two independent 
methods, melanoma-specific gene expression assays and 
immunofluorescent staining.
Our immunocytochemistry staining protocol 
identified CTCs expressing melanocytic markers in 43% 
of metastatic melanoma patients. However, this method 
would miss cells expressing melanoma-initiating markers. 
The evidence that a vast majority of melanoma CTCs 
express “stem cell” markers such as ABCB5, shown by 
flow cytometry and PAX3, by gene expression, argues for 
inclusion of such markers to increase the CTC detection 
rate by immunocytochemistry.
The most significant finding from this study is the 
detection of the expression of melanoma-specific genes 
in CTC fractions after slanted enrichment. We found 
melanoma-associated gene expression in 54% of analysed 
CTC fractions. All patients with CTCs positive by RT-
PCR for PAX3, ABCB5 or MLANA transcripts exhibited 
metastatic disease in distant organs (M1c) prior to 
treatment and two of the three cases with brain metastases 
were positive for PAX3 or MLANA. Interestingly, the fact 
that PAX3 and ABCB5 were detected in 6 out 7 cases 
with metastatic disease, positive by RT-PCR, might 
provide further evidence supporting the role of these 
genes in melanoma progression [14, 44, 47–50], but more 
importantly in the biology of melanoma CTCs. Thus, 
while this study was not aimed at determining a correlation 
between the expression of these melanoma-specific genes 
and clinical indicators, such as tumour burden or location, 
our findings warrant confirmation in a larger cohort.
Interestingly, PAX3 transcripts were detected in five 
out of the seven CTC positive cases, being co-expressed 
with ABCB5 in two of those. The specific role of PAX3 
in the biology of melanoma CTCs requires further 
investigation. PAX3 is a transcription factor that directs 
melanocytic differentiation from neural crest cells, and 
is involved in stem cell maintenance and cell migration 
of melanoblasts [51–54]. PAX3 is also highly expressed 
in primary and secondary melanoma tumours [47, 49]. 
It is possible that PAX3 might orchestrate melanoma 
metastasis by maintenance of the “stem cell” phenotype of 
these cells during migration [47, 51, 53, 54]. In addition, 
PAX3 has been described as a mediator of a drug-tolerance 
phase prior to the development of acquired resistance to 
targeted MAPK inhibition, via upregulation of MITF [55]. 
Figure 4: Melanoma-specific multimarker immunofluorescence staining for detection of melanoma CTCs. (A) 
Optimisation of immunostaining protocol in WBC samples spiked with A2058 cells, cytospun onto glass slides, fixed, permeabilised and 
immunostained with a combination of cell surface, MCSP (Alexa Fluor® 647, purple), and intracellular -MEL- (gp100, S100 and MLANA; 
Alexa Fluor® 488, green) markers. DAPI was used for nuclei staining and CD45 (PE, red) as a leukocytic marker. Differential expression of 
MCSP and MEL markers was observed in A2058 cells. (B) Representative melanoma CTCs detected by this immunofluorescence staining 
in metastatic melanoma patient blood processed twice through the slanted spiral microfluidic device. Melanoma CTCs had an average cell 
size of 16 μm (range: 13 – 21 μm). MCSP staining was not detected in any of the isolated melanoma CTCs from patient samples. Scale bar 
represents size of the cell in μm.
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Thus, the detection of PAX3 in CTC fractions might also 
have clinical implications. In this study, PAX3 transcripts 
were detected in two out of ten patients prior to MAPK 
treatment, and three out of ten pembrolizumab patients. 
Further study of the relationship between PAX3 expression 
in melanoma CTCs with early response to MAPK 
inhibitors, in a larger cohort of patients, may provide an 
insight into its role in the development of acquired 
resistance and its biomarker utility.
ABCB5, a tumour initiating or “stem cell” 
marker known to be involved in tumour resistance to 
chemotherapy and targeted therapy in melanoma, identifies 
a subset of slow-cycling tumour cells with increased 
potential to initiate metastases [44, 50, 56]. Previously, 
we reported [14] the expression of ABCB5 in unenriched 
whole blood from melanoma patients by RT-PCR and 
showed that ABCB5 transcripts were present in 40% of 
melanoma cases at all stages, particularly in those with 
disease recurrence (49%) and metastatic disease (52%). 
Here we found ABCB5 gene expression detected by RT-
PCR in 23% of all CTC-enriched patient samples with no 
detection of ABCB5 transcripts in ‘CTC fractions’ from 
healthy donors. ABCB5 was also found to be the most 
commonly expressed marker by melanoma CTCs detected 
by flow cytometry in unenriched and enriched samples. 
These findings highlight the importance of ABCB5 in 
CTC biology and the intrinsic heterogeneous nature of 
melanoma CTCs. Thus, further molecular and functional 
studies aiming to investigate the role of ABCB5 in 
melanoma CTCs, and interrogate CTC phenotypes during 
disease evolution as well as throughout treatment will 
unveil the relationship between ABCB5 and melanoma 
progression.
The phenotypic and molecular heterogeneity of 
melanoma CTCs, reported in this study, indicate that 
the real heterogeneity of melanoma CTCs may still 
be underestimated. Previous studies have detected 
melanoma CTCs in 40% [11], 57% [16], 52% [10], 79% 
[13] of patients, using CellSearch® (Janssen Diagnostics 
LLC), isolation by size of epithelial tumour cells (ISET) 
platform, multimarker flow cytometry and the herringbone 
CTC-Chip, respectively. These rates are similar to the CTC 
detection rates we observed of 54% (RT-PCR) and 43% 
(immunostaining) in this study. However, it is likely that 
differences in the CTC detection rates across these studies 
may be attributed to the extraordinary heterogeneity of 
melanoma CTCs both within and between patients [10]. 
Based on previous studies [10, 15, 16], we expect that not 
all melanoma CTCs express the same markers. Therefore, 
it is possible that the current markers used in downstream 
approaches for CTC detection may constrain our ability 
to detect the vast majority of melanoma CTC types. 
Thus, studies aimed at the capture and study of the whole 
range of melanoma CTCs to identify the real diversity of 
these cells are urgently needed in order to pinpoint better 
markers that minimise false negative results.
Challenges in the isolation and detection of CTCs, 
particularly in melanoma, have hindered studies aiming 
at unveiling the molecular mechanisms underlying 
melanoma CTC biology relative to that of bulk tumour 
cell biology. Nevertheless, although we did not analyse 
patient-matched tumour samples in this study, we have 
previously compared melanoma cell subpopulations 
between patient matched blood and metastatic tumours 
[10]. This revealed that cell populations expressing 
melanoma initiating markers, such as ABCB5 and 
RANK, are more common amongst CTCs than in the 
matching tumour, suggesting a preferential selection for 
certain tumour cell subtypes in the blood. Thus, further 
investigation of CTC heterogeneity relative to tumour 
diversity will provide a much clearer understanding 
of the biology of CTCs and the metastatic process in 
melanoma. The isolation of viable melanoma CTCs may 
allow future biological characterisation through CTC-
derived cell cultures and xenotransplantation [18, 35–38]. 
Furthermore, research is required to validate the biomarker 
utility of viable CTCs, as indicated previously by label-
dependent methods [10–12, 16].
Ultimately, the isolation of viable, label-free 
heterogeneous populations of melanoma CTCs using this 
slanted enrichment device will facilitate future studies 
aimed at unveiling the molecular mechanisms and biology 
of melanoma CTCs and their role in melanoma metastasis 
and response to therapy.
MATERIALS AND METHODS
Cell culture of melanoma cell lines
The melanoma cell lines 1205Lu, WM164, WM793 
were kindly provided by Professor Meenhard Herlyn from 
The Wistar Institute (Philadelphia, USA) and A2058, 
SKMEL5 and UACC62 were originally obtained from the 
American Type Culture Collection (ATCC, USA). Cell 
lines were cultured in high-glucose Dulbecco’s modified 
Eagle’s medium (DMEM) (Thermo Fisher Scientific) 
supplemented with 10% foetal bovine serum (FBS) 
(Thermo Fisher Scientific). The cultures were maintained 
at 37°C in a humidified atmosphere containing 5% (v/v) 
CO
2
 until 80% confluence. Cell lines were passaged 
every 72 hours as per ATCC guidelines. Sub-confluent 
monolayers were dissociated using 0.5% trypsin-EDTA 
in 1X phosphate buffered saline (PBS) solution (137 
mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH of 7.4) 
(Thermo Fisher Scientific).
Flow cytometry was used to identify the different cell 
sizes of melanoma cell lines. Cell lines with greater than 
80% viability, were washed twice with FACS buffer (0.1% 
bovine serum albumin, 100 mM EDTA, 10 mM HEPES, 
phosphate-buffered saline) and immediately acquired in 
a Gallios flow cytometer (Beckman Coulter). Cell sizes 
were inferred from the respective forward scatter values 
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for each cell line in an analysis performed using the Kaluza 
Analysis Software (Beckman Coulter). Additionally, the 
cell size of A2058 and SKMEL5 melanoma cell lines, 
during 5 consecutive passages, was measured in a Vi-
CELL XR cell counter (Beckman Coulter).
Healthy volunteers and metastatic melanoma 
patients
Twenty melanoma patients with metastatic disease, 
at baseline, prior to clinical treatment with targeted 
inhibitors or immunotherapies, were included in the 
present study (Table 1). Healthy volunteers and melanoma 
patients signed consent forms approved by the Human 
Research Ethics Committees at Edith Cowan University 
(No. 11543), Sir Charles Gairdner Hospital (No. 2013-
246) and South Metropolitan WA Health Service. For 
each patient, two BD Vacutainer K2 EDTA tubes (BD 
Biosciences) were collected and shipped to our research 
laboratory for sample processing within 24 hours post 
blood collection. The first five millilitres of blood were 
discarded to avoid epithelial contamination.
Spiking of melanoma cell lines into blood of 
healthy controls
The melanoma cell lines with the greatest 
differential cell diameter, A2058 and SKMEL5, were 
used to determine the efficiency of the slanted spiral 
microfluidic device to isolate melanoma cells spiked 
into blood from healthy donors. Cells were stained 
with CellTracker™ Red CMTPX dye (Thermo Fisher 
Scientific), and 1, 5, 10, 50 or 100 live-stained melanoma 
cells were manually counted and spiked into 8 mL of 
blood. Experiments were performed in triplicate for each 
melanoma cell line.
Recovery and purity of the slanted spiral 
microfluidic device
Before processing the spiked blood samples through 
the slanted device, blood samples were incubated with 
red blood cell (RBC) lysis buffer (140 mM NH
4
Cl, 17 
mM Tris, pH 7.65) for 10 mins at room temperature with 
continuous gentle mixing. Lysed RBCs were subsequently 
removed after centrifugation at 300 g for 5 min and the 
nucleated cell fraction was washed twice with 20 mL of 
PBS before resuspension into 16 mL (0.5x concentration) 
of PBS supplemented with 0.5% bovine serum albumin 
(0.5% BSA/PBS). Nucleated cells from blood were 
processed through the slanted spiral microfluidic device as 
described by Warkiani et al. [24] (Supplementary Figure 
1). Briefly, the slanted chips were washed with ethanol 
70% and PBS before being primed with 0.5% BSA/PBS 
solution prior to sample processing. Melanoma cells were 
isolated by processing 16 mL of the nucleated cells in 
0.5% BSA/PBS solution through the slanted spiral device 
at an input flow rate of 1700 μL min−1 controlled by a 
syringe pump (PHD 2000, Harvard Apparatus).
The slanted spiral device allows recovery from two 
outlets: one containing the recovered melanoma cells 
(CTC outlet) and the other containing the remaining white 
blood cells (waste outlet). To assess the recovery rate of 
this spiral device, the cellular fraction from the CTC outlet 
was transferred to a 48-well plate (Greiner Bio-One), and 
centrifuged at 500 g for 5 mins. Recovery rates were 
determined by counting the CellTracker™ red-labelled 
cells in an inverted fluorescent microscope (Eclipse Ti-
E, Nikon®) and the NIS-Elements High Content Analysis 
software, version 4.2 (Nikon®). Purity of the slanted 
enrichment was determined by counting the total number 
of WBCs in the CTC fraction using a haemocytometer.
To increase the purity of the CTC fractions, we 
evaluated the recovery rates and WBC background after 
processing the sample twice through the slanted device 
(2X slanted). For this, 50 labelled cells derived from 
A2058 and SKMEL5 cell lines were spiked into 8 mL 
of blood from 4 healthy donors. The cellular fraction of 
the CTC outlet from the first round of slanted enrichment 
was resuspended in a total volume of 6 mL of 0.5% BSA/
PBS solution and re-processed through the same washed 
and primed slanted device at the same flow rate. Cell 
Tracker™ red-labelled melanoma cells were counted as 
above and WBCs were counted in the nucleated fraction 
prior to enrichment, and in the ‘CTC’ fraction after 1st and 
2nd rounds of enrichment.
Isolation of CTCs from metastatic melanoma 
patients using the slanted spiral device
A total of 8 mL of blood were processed through 
the slanted microfluidic device. CTCs were enriched 
by processing the sample twice through the slanted 
microfluidic device (2X slanted). After enrichment, RNA 
was isolated using RNeasy Mini Kit (Qiagen) and stored 
at -80°C until further use.
Detection of melanoma CTCs by flow cytometry
An aliquot of 8 mL of blood was processed by 
multimarker flow cytometry to confirm the presence 
of CTCs after microfluidic enrichment, as described by 
Gray et al. [10]. For this, blood samples were processed 
once through the slanted spiral device (1X slanted) 
and the enriched CTC fraction was then assessed for 
melanoma CTC subpopulations using our multimarker 
flow cytometry assay and the same gating strategies as 
previously described [10]. A total of 1 x 105 WBCs from 
the waste outlet of the slanted device, were used as an 
isotype control for CTCs from the same patient sample, 
enriched via the device. The total and subpopulation-
specific CTC counts were compared pre- and post-
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enrichment for every patient. For this, two additional 
aliquots of 8 mL of blood, one as an isotype control and 
the other as a pre-enrichment test sample, were collected 
and processed at the same time and from the same patient 
as the samples used for microfluidic enrichment.
Gene expression assay to confirm CTC isolation
As previously described by Reid et al. [40], the 
expression of a panel of 5 melanoma-specific genes were 
assessed to confirm the presence of melanoma CTCs after 
slanted enrichment. Briefly, RNA (6 μL) isolated from 
cells from the enriched ‘CTC fraction’, for both spiked 
samples and patient blood, was reverse transcribed to 
cDNA using SuperScript® VILO™ master mix (Thermo 
Fisher Scientific, US) in a 10 μL final volume reaction. 
Subsequently, MLANA, TYR, MAGEA3, ABCB5 and 
PAX3 genes were preamplified in a reaction containing 
5 μL of input cDNA, 0.2X of a mixture of the TaqMan 
assays targeting these genes and the TaqMan® PreAmp 
Master Mix (Thermo Fisher Scientific). Expression of 
each of the 5 genes was then determined by qPCR of the 
preamplified cDNA using commercially designed TaqMan 
Gene Expression assays for each target gene. The 18S 
rRNA gene was used as an endogenous control. Cycling 
conditions and fluorescence detection of these PCR 
reactions were carried out in a ViiA™ 7 Real-Time PCR 
system (Thermo Fisher Scientific) [40]. Expression values 
were represented as the reciprocal Ct value for each target 
gene and plotted in a heatmap using the HeatMapViewer 
module (version 13.9; Broad Institute) at the GenePattern 
platform [57]. RNA isolated from cells in the CTC outlet 
after processing the blood of healthy individuals and from 
a sample spiked with 20 A2058 cells were included as 
negative and positive controls, respectively.
Immunofluorescence staining
Immediately after the second round of slanted 
enrichment, cells within the ‘CTC-enriched fraction’ were 
fixed by 10 min incubation with 4% Paraformaldehyde 
(PFA) and subsequently cytospun (Cytospin™ 4, Thermo 
Fisher Scientific) onto a glass slide at 2000 rpm for 5 
mins. Cells were again fixed with 4% PFA for 10 mins, 
then incubated in a blocking buffer containing 10% 
normal donkey serum (NDS), 3% bovine serum albumin 
(BSA) and 0.2% Triton X-100 (TX-100) in PBS for 15 
mins. Cells were then stained in a 1 hour incubation 
with blocking buffer and a cocktail of the following 
antibodies: rabbit anti-gp100 (clone EPR4864, Abcam), 
rabbit anti-MLANA/MART1 (clone EP1422Y, Abcam), 
rabbit anti-S100 (clone EP1576Y, Abcam), mouse anti-
MCSP conjugated to Alexa Fluor® 647 dye (clone 9.2.27, 
BD Pharmingen™) and mouse anti-CD45 conjugated 
to Phycoerythrin (PE) (clone HI30, BD Pharmingen™). 
Following incubation, cells were washed three times 
with 0.2% TX-100/PBS solution, and incubated with a 
donkey anti-rabbit IgG antibody conjugated to Alexa 
Fluor® 488 dye (Abcam) in blocking buffer. Finally, cells 
were mounted using ProLong® Gold Antifade Mountant 
with DAPI (4',6-diamidino-2-phenylindole) nuclear stain 
reagent (Thermo Fisher Scientific). Slides were stored 
at 4°C, visualised and scanned using the Eclipse Ti-E 
inverted fluorescent microscope (Nikon®). Stained cells 
were analysed using the NIS-Elements High Content 
Analysis software, version 4.2 (Nikon®) by two trained 
researchers. Background subtraction parameters for each 
marker, derived from immunostaining of A2058 melanoma 
cells spiked into WBC fractions, were stringently applied 
to all stained slides from patients’ CTC-enriched samples. 
After background subtraction, signal for each fluorescent 
dye was also adjusted to enhance the staining for each 
marker and parameters were applied to all stained 
slides. Only cells with confirmed positive staining, after 
background subtraction, for either MCSP, MEL or both 
and negative for the leukocytic marker CD45 were deemed 
as melanoma CTCs by consensus of multiple authors.
Statistical analysis
A two-tailed independent t-test was used to compare 
the mean cell diameters of A2058 and SKMEL cells. 
One-way ANOVA analyses were used to find statistical 
differences in the recovery rates for A2058 and SKMEL5 
cell lines between different spiked concentrations after 
1X slanted enrichment. Similarly, one-way ANOVA was 
used to determine the efficiency of the slanted device to 
deplete WBCs after the second round of enrichment with 
this device processing blood samples from controls and 
patients. Statistical significance was reached with a P 
<0.05.
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